Podcast: A Conversation with FDA’s OPQ Director Michael Kopcha
This article was originally published in RPM Report
Office of Pharmaceutical Quality Director Michael Kopcha discusses the allure of coming to FDA from the private sector and working with CDER Director Janet Woodcock, OPQ’s role in the “Breakthrough Therapy” designation process, the competitive advantages of continuous manufacturing, and priorities for OPQ moving forward.
You may also be interested in...
With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years. This is Part II in the series.
With two landmark advisory committee meetings coming up, the Pink Sheet reflects on some of the most memorable panel meetings over the last 20 years.
NASEM is expected to issue a highly anticipated report in early 2021 on solutions to address Rx vial drug wastage.